Home

Flagship Ventures Fund 2007, L.P.

CIK 1508052 · last filed 2016-09-26

Flagship Ventures Fund 2007, L.P. is a corporate insider who has filed 6 SEC Form 4 insider transactions across 6 companies since 2013. The most recent filing shows the insider sold $9.8M of EBIO on Sep 26, 2016. Across all open-market trades the lifetime net is +$16.8M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $130.3M across reported positions. The firm reports its address in Cambridge, MA. 28 SEC filings were submitted jointly with Flagship Ventures 2007 General Partner LLC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$130.27M

Companies

6

Total Filings

6

Lifetime Open-Market Net

$16.83M

Filer Profile

Reported Address
55 CAMBRIDGE PARKWAY, 8TH FLOOR
CAMBRIDGE, MA 02142
Phone
(617) 868-1888
State of Incorporation
DE
Related Filers
Flagship Ventures 2007 General Partner LLC — 28 joint filings, latest 2019-10-31
NOUBAR AFEYAN — 27 joint filings, latest 2019-10-31
Edwin Kania — 23 joint filings, latest 2019-05-15
Flagship Ventures Fund IV General Partner LLC — 16 joint filings, latest 2019-10-31
Flagship Ventures Fund IV, L.P. — 16 joint filings, latest 2019-10-31
Flagship Ventures Fund IV-Rx, L.P. — 11 joint filings, latest 2019-05-15
Flagship VentureLabs IV, LLC — 6 joint filings, latest 2019-05-15
Cadena LLC — 2 joint filings, latest 2019-03-06
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Carisma Therapeutics Inc. (EBIO) Delisted 10%+ Owner 668,912 — — -$9.82M 1 2016-09-26
Cartesian Therapeutics, Inc. (SELB) Delisted 10%+ Owner 1,216,367 $0.88 $1.07M $0 1 2016-06-29
MCRB 10%+ Owner 110,280 $5.01 $552.5K $0 1 2015-06-29
AGIO 10%+ Owner 3,860,738 $33.60 $129.72M $0 1 2013-07-31
Receptos, Inc. (RCPT) Delisted 10%+ Owner 1,817,197 — — $6.00M 1 2013-05-14
TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted 10%+ Owner 58,289 — — $20.66M 1 2013-03-27

Recent Filings

6 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2016-09-26 Carisma Therapeutics Inc. (EBIO) Delisted Sell (S) −3,103,954 -$9.82M EDGAR
2016-06-29 Cartesian Therapeutics, Inc. (SELB) Delisted Conv (C) +4,862,241 $0 EDGAR
2015-06-29 MCRB Mixed +81,391,240 $0 EDGAR
2013-07-31 AGIO Conv (C) +15,442,952 $0 EDGAR
2013-05-14 Receptos, Inc. (RCPT) Delisted Mixed +7,240,216 $47.23M EDGAR
2013-03-27 TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted Mixed +12,346,038 $20.66M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.